Loading…
Based on limited metadata with no full letter text available, NeuroXPF received an FDA Warning Letter dated March 31, 2020 regarding drug products. The specific nature of the violations cannot be determined from the available information, as no subject line details were provided in the metadata. This warning was issued by the FDA's drug regulatory division, though the specific issuing office is not identified in the available records.